摘要
摘要：目的：研究分析经验性使用莫西沙星对急性肺脓肿患者治疗的临床疗效以及相关的安全性。方法： 此次研究的对象是选择 100例急性肺脓肿患者，将其临床资料进行回顾性分析，并随机分为观察组和对照组，各 50例。对照组患者使用常规治疗方法即头孢哌酮舒巴坦联合替硝唑进行治疗，观察组患者使用静脉滴注莫西沙星的方法进行治疗。两组患者经过治疗完成后比较两组患者的治疗效果以及并发症发生率。结果：两组患者在经过治疗后均有所好转，但观察组患者的治疗效果明显相比对照组患者并不明显，观察组患者的治疗总有效率 94%，对照组患者的治疗总有效率 92%，差异不明显（ P>0.05），无统计学意义。同时观察组患者的并发症发生率 4%明显优于对照组患者的并发症发生率 12%，差异为显著性差异（ P<0.05），有统计学意义。结论：在对急性肺脓肿患者进行治疗的过程中，经验性的使用莫西沙星对患者进行治疗，治疗效果与头孢哌酮舒巴坦联合替硝唑类似，但莫西沙星的治疗方法能够减少患者的并发症发生率，安全性更高，在临床上值得推广应用。
关键词：经验性使用莫西沙星；急性肺脓肿；临床疗效；安全性
Abstract: Objective: To study and analyze the clinical efficacy and safety of moxifloxacin in the treatment of acute lung abscess. Methods: 100 patients with acute lung abscess were selected and their clinical data were analyzed retrospectively. They were randomly divided into observation group and control group with 50 cases in each group. The patients in the control group were treated with cefoperazone sulbactam and Tinidazole, while the patients in the observation group were treated with moxifloxacin. Two groups of patients after the completion of treatment compared with the two groups of patients' treatment effect and the incidence of complications. Results: the two groups of patients improved after treatment, but the treatment effect of the observation group was significantly less than that of the control group, the total effective rate of the observation group was 94%, the total effective rate of the control group was 92%, the difference was not significant (P > 0.05), no statistical significance. At the same time, the complication rate of 4% in the observation group was significantly higher than that of 12% in the control group, the difference was statistically significant (P < 0.05). Conclusion: in the treatment of acute lung abscess, moxifloxacin is used empirically. The effect of moxifloxacin is similar to that of cefoperazone sulbactam combined with tinidazole, but moxifloxacin can reduce the incidence of complications and has higher safety. It is worth popularizing and applying in clinic.
出版日期
2020年01月13日（中国期刊网平台首次上网日期，不代表论文的发表时间）
